Tag

UF Health

Atsena Therapeutics Announces Positive 12-Month Safety and Efficacy Data From Ongoing Phase I/II Clinical Trial To Treat Leber Congenital Amaurosis

Atsena Therapeutics announced positive results in their 12-month safety and efficacy data from the ongoing Phase I/II trial of ATSN-101, the company’s investigational gene therapy for the treatment of GUCY2D-associated Leber congenital amaurosis (LCA1). At 12 months post-treatment, ATSN-101 has conferred clinically meaningful improvements in vision at the highest dose with no serious treatment-emergent adverse events.

UF Brain Institute Receives $1 Million for Stroke Research Project

The University of Florida’s McKnight Brain Institute received $1 million to support a stroke research project. The funds are part of UF President Ben Sasse’s $10.9 million strategic funding initiative aimed at boosting the university's position as a leader in critical research. The funds will be used to launch a new project that utilizes AI to improve stroke treatments.

Tech Tuesday – Cherie Stabler

In this week's Tech Tuesday for WCJB TV20, UF Innovate's Melanie Morón interviews Cherie Stabler, researcher and professor in the UF Department of Biomedical Engineering, who is conducting research on a possible cure for type 1 diabetes.

Tech Tuesday – Tyler Loftus

On this Tech Tuesday segment, Melanie Morón interviews Tyler Loftus, a trauma surgeon in the UF Department of Surgery whose research focuses on improving patient care in ICU setting using AI.

Tech Tuesday: Maribel Ciampitti

On this Tech Tuesday segment, Melanie Morón interviews Maribel Ciampitti from the UF College of Medicine Jacksonville to discuss her recent invention aimed at assisting patients with respiratory muscle strength training.